Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Background/Aims: To eliminate hepatitis B virus (HBV) and hepatitis C virus (HCV) according to the World Health Organization (WHO) criteria in 2021, this study investigated the national core indicators representing the current status of viral hepatitis B and C in South Korea. Methods: We analyzed the incidence, linkage-to-care, treatment, and mortality rates of HBV and HCV infection using the integrated nationwide big data of South Korea. Results: According to data from 2018–2020, the incidence of acute HBV infection in South Korea was 0.71 cases per 100,000 population; tthe linkage-to-care rate was only 39.4%. Among those who need hepatitis B treatment, the treatment rate was 67.3%, which was less than 80% reported in the WHO program index. The annual liver-related mortality due to HBV was 18.85 cases per 100,000 population, exceeding the WHO target of four; the most frequent cause of death was liver cancer (54.1%). The annual incidence of newly diagnosed HCV infection was 11.9 cases per 100,000 population, which was higher than the WHO impact target of five. Among HCV-infected patients, the linkage-to-care rate was 65.5% while the treatment rate was 56.8%, which were below the targets of 90% and 80%, respectively. The liver-related annual mortality rate due to HCV infection was 2.02 cases per 100,000 population. Conclusions: Many of the current indicators identified in the Korean population did not satisfy the WHO criteria for validation of viral hepatitis elimination. Hence, a comprehensive national strategy should be urgently developed with continuous monitoring of the targets in South Korea.
Abstract
Background/Aims: To eliminate hepatitis B virus (HBV) and hepatitis C virus (HCV) according to the World Health Organization (WHO) criteria in 2021, this study investigated the national core indicators representing the current status of viral hepatitis B and C in South Korea. Methods: We analyzed the incidence, linkage-to-care, treatment, and mortality rates of HBV and HCV infection using the integrated nationwide big data of South Korea. Results: According to data from 2018–2020, the incidence of acute HBV infection in South Korea was 0.71 cases per 100,000 population; tthe linkage-to-care rate was only 39.4%. Among those who need hepatitis B treatment, the treatment rate was 67.3%, which was less than 80% reported in the WHO program index. The annual liver-related mortality due to HBV was 18.85 cases per 100,000 population, exceeding the WHO target of four; the most frequent cause of death was liver cancer (54.1%). The annual incidence of newly diagnosed HCV infection was 11.9 cases per 100,000 population, which was higher than the WHO impact target of five. Among HCV-infected patients, the linkage-to-care rate was 65.5% while the treatment rate was 56.8%, which were below the targets of 90% and 80%, respectively. The liver-related annual mortality rate due to HCV infection was 2.02 cases per 100,000 population. Conclusions: Many of the current indicators identified in the Korean population did not satisfy the WHO criteria for validation of viral hepatitis elimination. Hence, a comprehensive national strategy should be urgently developed with continuous monitoring of the targets in South Korea.
참고문헌 (46)
- "Hepatitis B"[URL]
- "Global hepatitis report, 2017"[URL]
- Thomas DL, "Global elimination of chronic hepatitis", N Engl J Med, 380, pp.2041~2050 (2019)
- Foreman KJ, "Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death : reference and alternative scenarios for 2016-40 for 195countries and territories", Lancet, 392, pp.2052~2090 (2018)
- Global health sector strategy on viral hepatitis 2016-2021. Towards ending viral hepatitis, "World Health Organization", World Health Organization, ~ (2016)
- World Health Organization, "Interim guidance for country validation of viral hepatitis elimination", World Health Organization, ~ (2021)
- Viral Hepatitis National Strategic Plan for the United States: A Roadmap to Elimination (2021–2025), "US Department of Health and Human Services", US Department of Health and Human Services, ~ (2020)
- "Reducing the health impact of sexually transmitted and blood-borne infections in Canada by 2030: A pan-Canadian STBBI framework for action"[URL]
- Taiwan Ministry of Health and Welfare, "Taiwan Hepatitis C Policy Guidelines 2018-2025", Taiwan Ministry of Health and Welfare, ~ (2018)
- Ko K, "Epidemiology of viral hepatitis C : Road to elimination in Japan", Glob Health Med, 3, pp.262~269 (2021)
- Hassanin A, "Egypt's ambitious strategy to eliminate hepatitis c virus : A case study", Glob Health Sci Pract, 9, pp.187~200 (2021)
- Shiha G, "Reduced incidence of hepatitis C in 9 villages in rural Egypt : Progress towards national elimination goals", J Hepatol, 74, pp.303~311 (2021)
- Criteria for validation of elimination of viral hepatitis B and C : report of seven country pilots, "World Health Organization", World Health Organization, ~ (2022)
- 임선영, "The epidemiology of hepatitis B virus infection in Korea", The Korean Journal of Internal Medicine, 34(5), pp.945~953 (2019), 대한내과학회[DOI]
- Do Young Kim, "History and future of hepatitis B virus control in South Korea", Clinical and Molecular Hepatology, 27(4), pp.620~622 (2021), 대한간학회[DOI]
- Lee EY, "Trends of liver cancer and its major risk factors in Korea", Epidemiol Health, 37, pp.e2015016~ (2015)
- Sungchul Choi, "Global burden of primary liver cancer and its association with underlying aetiologies, sociodemographic status, and sex differences from 1990–2019: A DALY-based analysis of the Global Burden of Disease 2019 study", Clinical and Molecular Hepatology, 29(2), pp.433~452 (2023), 대한간학회
- "Health insurance coverage and population"[URL]
- Seong SC, "Data resource profile : The national health information database of the national health insurance service in South Korea", Int J Epidemiol, 46, pp.799~800 (2017)
- Lim YS, "Impact of expanding hepatitis B treatment guidelines : A modelling and economic impact analysis", Aliment Pharmacol Ther, 56, pp.519~528 (2022)
- Kyung-Ah Kim, "Prevalence, Awareness, and Treatment of Hepatitis C Virus Infection in South Korea: Evidence from the Korea National Health and Nutrition Examination Survey", Gut and Liver, 14(5), pp.644~651 (2020), 거트앤리버 소화기연관학회협의회[DOI]
- "National Health Statistics 2020"[URL]
- "Korea Statistical Information Service"[URL]
- Lok AS, "Antiviral therapy for chronic hepatitis B viral infection in adults : A systematic review and meta-analysis", Hepatology, 63, pp.284~306 (2016)
- Wong GL, "Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis", Hepatology, 58, pp.1537~1547 (2013)
- The Korean Association for the Study of the Liver, "KASL clinical practice guidelines for management of chronic hepatitis B", Clinical and Molecular Hepatology, 28(2), pp.276~331 (2022), 대한간학회
- Terrault NA, "Update on prevention, diagnosis, and treatment of chronic hepatitis B : AASLD 2018 hepatitis B guidance", Hepatology, 67, pp.1560~1599 (2018)
- European Association for the Study of the Liver, "EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection", J Hepatol, 67, pp.370~398 (2017)
- Sarin SK, "Asian-Pacific clinical practice guidelines on the management of hepatitis B : a 2015 update", Hepatol Int, 10, pp.1~98 (2016)
- Jeong-Ju Yoo, "Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase", Clinical and Molecular Hepatology, 29(2), pp.482~495 (2023), 대한간학회
- Choi WM, "Increasing on-treatment hepatocellular carcinoma risk with decreasing baseline viral load in HBeAg-positive chronic hepatitis B", J Clin Invest, 132, pp.e154833~ (2022)
- "National Health Statistics 2021"[URL]
- "2021 Hepatitis C Factsheet"[URL]
- Chon Young Eun, "The Incidence and Care Cascade of the Hepatitis C Virus in Korea", Gut and Liver, 17(6), pp.926~932 (2023), 거트앤리버 소화기연관학회협의회[DOI]
- HIV Modelling Consortium Treatment as Prevention Editorial Writing Group, "HIV treatment as prevention : models, data, and questions--towards evidence-based decision-making", PLoS Med, 9, pp.e1001259~ (2012)
- Martin NK, "Hepatitis C virus treatment for prevention among people who inject drugs : Modeling treatment scale-up in the age of direct-acting antivirals", Hepatology, 58, pp.1598~1609 (2013)
- Stone J, "Modelling the impact of incarceration and prison-based hepatitis C virus(HCV)treatment on HCV transmission among people who inject drugs in Scotland", Addiction, 112, pp.1302~1314 (2017)
- Bretaña NA, "Combined treatment and prevention strategies for hepatitis C virus elimination in the prisons in New South Wales : a modelling study", Addiction, 115, pp.901~913 (2020)
- Omar Alshuwaykh, "Current and future strategies for the treatment of chronic hepatitis C", Clinical and Molecular Hepatology, 27(2), pp.246~256 (2021), 대한간학회[DOI]
- Kim DY, "Estimating the cost-effectiveness of one-time screening and treatment for hepatitis C in Korea", PLoS One, 12, pp.e0167770~ (2017)
- Kim KA, "Cost-effectiveness and health-related outcomes of screening for hepatitis C in Korean population", Liver Int, 39, pp.60~69 (2019)
- Kim DY, "Costeffectiveness of increased screening and treatment of chronic hepatitis C in Korea", Curr Med Res Opin, 36, pp.993~1002 (2020)
- Hye-Lin Kim, "A cost-effectiveness study of universal screening for hepatitis C virus infection in South Korea: A societal perspective", Clinical and Molecular Hepatology, 28(1), pp.91~104 (2022), 대한간학회[DOI]
- 이혜원, "Cost-effectiveness of chronic hepatitis C screening and treatment", Clinical and Molecular Hepatology, 28(2), pp.164~173 (2022), 대한간학회[DOI]
- Rockey DC, "Fibrosis regression after eradication of hepatitis C virus : From bench to bedside", Gastroenterology, 160, pp.1502~1520 (2021)
- Tanaka Y, "HCC risk post-SVR with DAAs in East Asians : findings from the REAL-C cohort", Hepatol Int, 14, pp.1023~1033 (2020)